Retrospective observation of the curative effect of Yiqi Zhuyu Jiedu granule combined with antiviral drugs on patients with chronic hepatitis B liver fibrosis and cirrhosis with low-level viremia
Objective:First,we aim to evaluate the clinical efficacy of Yiqi Zhuyu Jiedu granule in the treatment of chronic hepatitis B liver fibrosis and cirrhosis with low-level viremia(liver-stagnation and spleen-deficiency type).Secondly,we aim to evaluate whether there are differences in the treatment of chronic hepatitis B liver fibrosis with Yiqi Zhuyu Jiedu granule combined with different antiviral drugs.Methods:A total of 165 patients with chronic hepatitis B liver fibrosis and cirrhosis with low-level viremia treated with oral antiviral drugs(ETV or TDF or TAF)plus Yiqi Zhuyu Jiedu granules were collected from January 2019 to December 2022 in the outpatient clinic of Professor Li Hui in the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.They were defined as Chinese medicine combined with antiviral drug treatment group.The LSM value was divided into three degrees:mild fibrosis(39 cases),significant/advanced liver fibrosis(54 cases),and cirrhosis(72 cases).The LSM value,FIB-4,APRI,GPR,and S index before and after the treatment of the above patients with Chinese traditional medicine course for three months were retrospectively analyzed,and the efficacy was analyzed.In addition,165 patients were divided into Chinese medicine combined with the ETV treatment group(94 cases)and Chinese medicine combined with TDF/TAF treatment group(71 cases),which were divided into three degrees according to LSM value.The above indexes were compared between Chinese medicine combined with ETV treatment group(29 cases of mild liver fibrosis,27 cases of significant/advanced liver fibrosis,38 cases of cirrhosis)and Chinese medicine combined with TDF/TAF treatment group(10 cases of mild liver fibrosis,27 cases of significant/advanced liver fibrosis,34 cases of cirrhosis).Results:Firstly,the LSM value of mild fibrosis,significant/advanced liver fibrosis,and cirrhosis before and after three months of Chinese medicine treatment had significant differences in the Chinese medicine combined with antiviral drugs group(P＜0.01).Secondly,about FIB-4,APRI,GPR,and S index:only the cirrhosis patients before and after treatment showed statistical significance(P＜0.01),while the mild fibrosis and significant/advanced fibrosis patients showed no statistical significance in the Chinese medicine combined with antiviral drugs group.Thirdly,the effective rates of mild fibrosis,significant/advanced fibrosis,and cirrhosis in the Chinese medicine combined with antiviral drugs group were 46.15％,74.07％,and 63.89％,respectively,with a total effective rate of 63.03％(n=165).After Chi-square test,P＜0.05 indicates that at least two effective rates are different.Bonferroni method was used to compare mild fibrosis with significant/advanced liver fibrosis(P=0.006＜0.0167),and the comparison of pairwise effective rates was not statistically significant.Fourth,there were no statistically significant differences in baseline data between the two groups(P＞0.05),no statistically significant differences in LSM value,FIB-4,APRI,GPR,and S index before treatment(P＞0.05),and no statistically significant differences in LSM value,FIB-4,APRI,GPR,and S index after treatment(P＞0.05).Conclusion:Yiqi Zhuyu Jidu Granules are effective in chronic hepatitis B patients with liver fibrosis and cirrhosis with low-level viremia after long-term antiviral treatment(five years)for three months,and the effect of significant/progressive fibrosis is better than that of mild fibrosis.Yiqi Zhuyu Jiedu granule combined with different antiviral drugs(ETV or TDF/TAF)in the treatment of liver fibrosis and cirrhosis had no significant difference.
Yiqi Zhuyu Jiedu granuleschronic viral hepatitis Bliver fibrosiscirrhosislow-level viremia
万方数据
维普
